🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06832839
Recruiting Observational

Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease

NCT06832839 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Tiantan Hospital
Phase
Observational
Started
2024-12-16
Last updated
2025-02-18

Condition(s) studied

Moyamoya Disease

Investigational drug(s) / intervention(s)

Revascularization

Revascularization: Revascularization

Study summary

The purpose of this study is to comprehensively evaluate the risk factors for cognitive decline in patients with moyamoya disease, identify imaging target areas associated with cognitive damage in the brain, and explore the changes in brain structure and functional networks resulting from cerebral revascularization, as well as their relationship with cognitive improvement.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * The admission cerebral angiography (DSA) examination fulfills the diagnostic criteria for moyamoya disease. * Please sign the informed consent form. * Participants must be between 18 and 60 years of age. Exclusion Criteria: * Patients with concurrent atherosclerosis, autoimmune diseases, meningitis, brain tumors, Down syndrome, craniocerebral trauma, prior radioactive head irradiation, or hyperthyroidism, which may result in secondary cerebrovascular lesions leading to symptoms associated with smoke syndrome. * Individuals younger than 18 years or older than 60 years. * Those with contraindications for magnetic resonance imaging. * Patients who are unable to complete cognitive brain assessments

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Tiantan Hospital Beijing China Recruiting

More Beijing Tiantan Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06832839 on ClinicalTrials.gov ↗ ← All trials in China